Welcome to our dedicated page for Neurosense Therapeutics SEC filings (Ticker: NRSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeuroSense Therapeutics Ltd. (NRSN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. NeuroSense files current reports on Form 6-K and annual reports on Form 20-F under the Securities Exchange Act of 1934, detailing clinical, regulatory, corporate and financing developments related to its neurodegenerative disease programs.
In these filings, NeuroSense reports key milestones for its lead drug candidate PrimeC, a novel extended-release oral formulation that combines ciprofloxacin and celecoxib in a fixed dose. Recent 6-K reports have furnished press releases on topics such as FDA clearance to initiate a pivotal Phase 3 trial of PrimeC in ALS, database lock for the RoAD Phase 2 Alzheimer’s disease study, and biomarker findings indicating statistically significant reductions in Alzheimer’s disease–associated microRNAs.
Other 6-K submissions include notices and proxy statements for shareholder meetings, descriptions of private placement transactions in ordinary shares, and business updates that summarize clinical trial data, regulatory interactions with agencies like the FDA and Health Canada, and manufacturing scale-up activities. Certain 6-K reports state that they are incorporated by reference into NeuroSense’s registration statements on Form F-3 and Form S-8, which relate to securities offerings and equity compensation plans.
On Stock Titan, these filings are updated as they are released through EDGAR. AI-powered tools can help readers quickly understand the focus of each 6-K or 20-F by summarizing clinical trial disclosures, regulatory announcements, financing terms and shareholder matters. This allows investors and researchers to review NeuroSense’s official statements on the development of PrimeC in ALS and Alzheimer’s disease, corporate governance actions and capital-raising activities without reading every document in full.
NeuroSense Therapeutics Ltd. filed an initial ownership report showing that Chief Executive Officer and 10% owner Alon Ben-Noon holds several blocks of ordinary shares and warrants. He directly holds 3,175,266 Ordinary Shares, plus additional direct holdings of 641,524 and 360,777 Ordinary Shares. He also holds warrants to purchase 26,666 Ordinary Shares at an exercise price of $0.75 per share, expiring on August 14, 2029, and warrants to purchase 80,000 Ordinary Shares at an exercise price of $1.25 per share, expiring on December 4, 2029. Footnotes explain that these warrants and related shares were acquired in private placements on August 15, 2024 and December 5, 2024, and that certain restricted shares vest 75% on April 16, 2027 and May 19, 2027, with the remainder vesting later in 2027, subject to continued service and a business milestone.
Binder Hagit reported acquisition or exercise transactions in this Form 4 filing.
NeuroSense Therapeutics Ltd. granted General Manager Hagit Binder 200,000 Ordinary Shares as a share-based compensation award, recorded at a price of $0.0000 per share. Following this grant, Binder directly holds 521,806 Ordinary Shares.
The award consists of restricted shares that vest in equal quarterly installments over a two-year period starting on March 26, 2026, conditioned on Binder’s continued service with the company at each vesting date. To qualify for certain Israeli tax benefits under Section 102, the securities must be registered in the name of a trustee, but they are reported here as directly owned by Binder.
NeuroSense Therapeutics furnished a report describing regulatory and clinical progress for its lead drug candidate, PrimeC, targeting ALS and Alzheimer’s disease. A pre-New Drug Submission meeting with Health Canada has been rescheduled to May 2026 so the company can include additional clinical, biomarker and survival data, aiming to strengthen its case under Canada’s conditional approval pathway (NOC/c).
The company also expects to report clinical and biomarker results from its Alzheimer’s study in the coming weeks. Management believes the enhanced data package and upcoming readouts could support a more constructive regulatory dialogue and mark important potential value inflection points across its ALS and Alzheimer’s programs during 2026.
NeuroSense Therapeutics Ltd. director Christine A. Pellizzari filed an initial ownership report showing existing equity interests rather than new trades. The filing lists options to purchase 72,000 Ordinary Shares at an exercise price of $1.43 per share, expiring on March 10, 2032, which are fully vested and exercisable. It also discloses direct holdings of Ordinary Shares, including restricted shares that vest on December 30, 2026 and January 30, 2027, subject to continued service and achievement of specified business milestones.
NeuroSense Therapeutics Ltd. Chief Medical Officer Tracik Ferenc filed a Form 3 disclosing his existing equity stake in the company. The filing lists fully vested options to purchase 108,000 Ordinary Shares at an exercise price of $3.51 per share, expiring on October 31, 2031, and warrants to purchase 66,667 Ordinary Shares at an exercise price of $0.75 per share, expiring on August 14, 2029. It also notes direct holdings of Ordinary Shares and includes restricted shares that vest in 2027 or earlier upon achieving a specified business milestone.
NeuroSense Therapeutics Ltd. director Mark Leuchtenberger filed an initial ownership report showing his existing equity position in the company. The filing lists options to purchase 192,000 ordinary shares at an exercise price of $3.51 per share, expiring on October 31, 2031, which are fully vested and exercisable.
He also reports direct holdings of ordinary shares in several blocks, including 128,000 shares, 75,000 shares, and 122,951 restricted shares. Some of these restricted shares are scheduled to vest on December 30, 2026 and January 30, 2027, subject to his continued service and the achievement of specified business milestones.
NeuroSense Therapeutics Ltd. officer Hagit Binder, serving as General Manager, has filed a Form 3 showing her current equity interests in the company. She directly holds ordinary shares listed in several line items, including 12,836 shares, 32,000 shares and 266,970 shares.
Binder also holds options to purchase 36,000 ordinary shares at an exercise price of $1.9900 per share, expiring on October 12, 2032; these options are fully vested and exercisable. In addition, she holds 10,000 restricted share units that are scheduled to vest on April 1, 2026. Certain plan-related securities are held through a trustee to qualify for tax benefits under Israeli law.
NeuroSense Therapeutics Ltd. director Claiborne Cary J filed an initial ownership report, detailing existing equity positions rather than new trades. The filing lists options to purchase 72,000 Ordinary Shares at an exercise price of $1.43 per share, expiring on March 10, 2032, which are fully vested and exercisable. It also discloses multiple blocks of Ordinary Shares held directly, including restricted shares that vest on December 30, 2026 and January 30, 2027, with potential accelerated vesting if specified business milestones are achieved.
NeuroSense Therapeutics Ltd. director Golan Roy filed an initial Form 3 reporting his beneficial ownership of Ordinary Shares. This filing establishes his starting equity position as an insider of the company.
Footnotes indicate that certain restricted shares were granted under NeuroSense’s 2018 Share Incentive Plan and are held through a trustee to qualify for Israeli Section 102 tax benefits. These restricted shares are scheduled to vest on December 30, 2026 and January 30, 2027, subject to his continued service, with potential accelerated vesting if a specified business milestone described in his restricted share agreements is achieved.
NeuroSense Therapeutics reported that results from its multinational Phase 2b trial of PrimeC in amyotrophic lateral sclerosis (ALS) have been published in JAMA Neurology. The randomized, double-blind, placebo-controlled study enrolled 68 participants and included a 6‑month blinded period followed by a 12‑month open‑label extension.
Participants who received PrimeC from the outset maintained a 7.92‑point functional advantage on the ALSFRS‑R scale at 18 months, representing over 36% slowing of disease progression (p=0.007), with the largest benefit in the bulbar domain (p=0.001). ALS complication‑free survival showed a 64% relative risk reduction favoring early treatment (p=0.02).
The trial also showed biological activity consistent with PrimeC’s multi‑pathway mechanism, including favorable changes in iron metabolism markers and significant downregulation of ALS‑associated microRNAs. These data, together with good safety, helped shape NeuroSense’s Phase 3 trial of PrimeC, which has received FDA clearance to proceed.